IL6 and inflammatory bowel disease: Correspondingly, the inhibition of IL-6 transsignaling, wherein the complex of IL-6 and sIL-6R can stimulate cells that do not express IL-6R (such as endothelial cells and smooth muscle cells), is sufficient to block disease in mouse models of inflammatory bowel disease and RA (40).